Treatment of lower respiratory tract infections with sultamicillin.
Oral tablets containing 375 mg sultamicillin were used to treat 30 adult patients of either sex suffering from lower respiratory tract infections. The dose used was one tablet every 12 h for 22 cases and one tablet every 8 h for eight cases. The duration of therapy varied between 5 and 14 days (mean 8.6 days). The therapeutic response was rated as cure in 23 (76.6%) patients, with complete disappearance of pretreatment signs and symptoms, and as improvement in seven (23.3%) patients, with amelioration of the pretreatment manifestations. All 52 microorganisms isolated before treatment were eradicated. No adverse effects were reported in 25 (83.3%) patients, whereas the remaining five (16.7%) patients reported mild loose stools with normal bowel motion. There were no abnormal changes in blood count and liver and renal functions following sultamicillin treatment.
Tageldin
M A
MA
Department of Chest Diseases, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Said
A
A
D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D011014:Pneumonia / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013407:Sulbactam / Q000627:therapeutic use*; D013607:Tablets
D013607:Tablets; C035444:sultamicillin; D000667:Ampicillin; D013407:Sulbactam